Japan’s Shionogi, AstraZeneca Sue Seven Generics For Violating Crestor Patent (Japan)
This article was originally published in PharmAsia News
Executive Summary
Japan's Shionogi joined with AstraZeneca in suing seven makers of generic drugs for applying in the United States for a version of Crestor (rosuvastatin calcium) for lowering cholesterol. Shionogi, the developer, said its U.S. patent for the drug is still in effect and the application violates it. AstraZeneca markets the drug. Defendants in the suit are Apotex, Aurobindo Pharma, Cobalt Pharmaceuticals, Mylan Pharmaceuticals, Pan Pharmaceuticals, Sandoz and Sun Pharmaceuticals. (Click here for more - may require a subscription
You may also be interested in...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.